Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Posted by Geri Gentry on Sep 16th, 2026

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.50.

Several research firms have commented on GANX. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, August 31st. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, August 11th.

Read Our Latest Report on GANX

Gain Therapeutics Price Performance

Shares of GANX opened at $1.71 on Wednesday. Gain Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $4.34. The firm’s 50-day simple moving average is $1.83 and its two-hundred day simple moving average is $1.92. The stock has a market cap of $74.62 million, a PE ratio of -3.42 and a beta of 0.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Analysts anticipate that Gain Therapeutics will post -0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Apollon Wealth Management LLC raised its stake in Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock valued at $51,000 after buying an additional 6,675 shares during the last quarter. Two Sigma Securities LLC purchased a new position in shares of Gain Therapeutics in the 2nd quarter worth $26,000. HB Wealth Management LLC purchased a new position in shares of Gain Therapeutics in the 2nd quarter worth $26,000. HighTower Advisors LLC bought a new stake in shares of Gain Therapeutics in the second quarter worth $35,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Gain Therapeutics in the second quarter worth $277,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

(Get Free Report)

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.